Disc Medicine Says FDA Engagement Over Bitopertin Remains Productive -- Market Talk

Dow Jones

Jan 14

1416 ET - Disc Medicine management maintained that their engagement with the FDA about approval for bitopertin remains constructive in an analyst event at the JPMorgan Healthcare Conference, BMO says in a note. The company is looking to dispel investor jitters about an article in STAT News reporting that Center for Biologics Evaluation and Research Director Vinay Prasad is skeptical about the bitopertin application. "Disc's management highlighted specifically (and again) that interaction with FDA remains productive and consistent with the company and FDA reviewers communicating frequently without mention of any alleged concerns from Prasad as it relates to bitopertin's submission," analysts writes, adding that BMO was impressed by Disc's commercial preparation for the drug.(elias.schisgall@wsj.com)

(END) Dow Jones Newswires

January 13, 2026 14:16 ET (19:16 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603632297"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603632297\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603632297?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 03:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603632297","market":"fut","top_or_hot":-1,"title":"Disc Medicine Says FDA Engagement Over Bitopertin Remains Productive -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1416 ET - <a href=\"https://laohu8.com/S/IRON\">Disc Medicine</a> management maintained that their engagement with the FDA about approval for bitopertin remains constructive in an analyst event at the JPMorgan Healthcare Conference, BMO says in a note. The company is looking to dispel investor jitters about an article in STAT News reporting that Center for Biologics Evaluation and Research Director Vinay Prasad is skeptical about the bitopertin application. \"Disc's management highlighted specifically (and again) that interaction with FDA remains productive and consistent with the company and FDA reviewers communicating frequently without mention of any alleged concerns from Prasad as it relates to bitopertin's submission,\" analysts writes, adding that BMO was impressed by Disc's commercial preparation for the drug.(elias.schisgall@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 14:16 ET (19:16 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disc Medicine Says FDA Engagement Over Bitopertin Remains Productive -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisc Medicine Says FDA Engagement Over Bitopertin Remains Productive -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-14 03:16</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1416 ET - <a href=\"https://laohu8.com/S/IRON\">Disc Medicine</a> management maintained that their engagement with the FDA about approval for bitopertin remains constructive in an analyst event at the JPMorgan Healthcare Conference, BMO says in a note. The company is looking to dispel investor jitters about an article in STAT News reporting that Center for Biologics Evaluation and Research Director Vinay Prasad is skeptical about the bitopertin application. \"Disc's management highlighted specifically (and again) that interaction with FDA remains productive and consistent with the company and FDA reviewers communicating frequently without mention of any alleged concerns from Prasad as it relates to bitopertin's submission,\" analysts writes, adding that BMO was impressed by Disc's commercial preparation for the drug.(elias.schisgall@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 14:16 ET (19:16 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603632297","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603632297","pubTimestamp":1768331760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1416 ET - Disc Medicine management maintained that their engagement with the FDA about approval for bitopertin remains constructive in an analyst event at the JPMorgan Healthcare Conference, BMO says in a note. The company is looking to dispel investor jitters about an article in STAT News reporting that Center for Biologics Evaluation and Research Director Vinay Prasad is skeptical about the bitopertin application. \"Disc's management highlighted specifically  that interaction with FDA remains productive and consistent with the company and FDA reviewers communicating frequently without mention of any alleged concerns from Prasad as it relates to bitopertin's submission,\" analysts writes, adding that BMO was impressed by Disc's commercial preparation for the drug.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","IRON":"Disc Medicine","BK4139":"生物科技"},"translate_title":"Disc Medicine表示FDA对Bitopertin的参与仍然富有成效——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRON":1.5},"content_text":"1416 ET - Disc Medicine management maintained that their engagement with the FDA about approval for bitopertin remains constructive in an analyst event at the JPMorgan Healthcare Conference, BMO says in a note. The company is looking to dispel investor jitters about an article in STAT News reporting that Center for Biologics Evaluation and Research Director Vinay Prasad is skeptical about the bitopertin application. \"Disc's management highlighted specifically (and again) that interaction with FDA remains productive and consistent with the company and FDA reviewers communicating frequently without mention of any alleged concerns from Prasad as it relates to bitopertin's submission,\" analysts writes, adding that BMO was impressed by Disc's commercial preparation for the drug.(elias.schisgall@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 14:16 ET (19:16 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}